Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Rheumatology and Therapy Année : 2021

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade

Résumé

It is unclear whether polymyalgia rheumatica (PMR) should be considered an inflammatory disease or an autoimmune disease.

Dates et versions

hal-03205677 , version 1 (22-04-2021)

Identifiants

Citer

Guillermo Carvajal Alegria, Divi Cornec, Yves Renaudineau, Alain Saraux, Valérie Devauchelle-Pensec. Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade. Rheumatology and Therapy, 2021, ⟨10.1007/s40744-021-00299-8⟩. ⟨hal-03205677⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More